211 related articles for article (PubMed ID: 33967177)
1. Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining
Hatakeyama J; Ono T; Takahashi M; Oda M; Shimizu H
Neurol Med Chir (Tokyo); 2021 Jun; 61(6):367-375. PubMed ID: 33967177
[TBL] [Abstract][Full Text] [Related]
2.
Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.
Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H
J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558
[TBL] [Abstract][Full Text] [Related]
4. Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography.
Yamashita K; Yoshiura T; Hiwatashi A; Togao O; Yoshimoto K; Suzuki SO; Abe K; Kikuchi K; Maruoka Y; Mizoguchi M; Iwaki T; Honda H
Neuroradiology; 2013 Feb; 55(2):135-43. PubMed ID: 22961074
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
[TBL] [Abstract][Full Text] [Related]
6. Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging.
You SH; Yun TJ; Choi HJ; Yoo RE; Kang KM; Choi SH; Kim JH; Sohn CH
Eur Radiol; 2018 Sep; 28(9):3801-3810. PubMed ID: 29619520
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of
Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
[TBL] [Abstract][Full Text] [Related]
9. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma?
Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T
World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204
[TBL] [Abstract][Full Text] [Related]
10. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
[TBL] [Abstract][Full Text] [Related]
11.
Kong Z; Jiang C; Zhu R; Feng S; Wang Y; Li J; Chen W; Liu P; Zhao D; Ma W; Wang Y; Cheng X
Neuroimage Clin; 2019; 23():101912. PubMed ID: 31491820
[TBL] [Abstract][Full Text] [Related]
12. Atypical primary central nervous system lymphoma and glioblastoma: multiparametric differentiation based on non-enhancing volume, apparent diffusion coefficient, and arterial spin labeling.
Yu X; Hong W; Ye M; Lai M; Shi C; Li L; Ye K; Xu J; Ai R; Shan C; Cai L; Luo L
Eur Radiol; 2023 Aug; 33(8):5357-5367. PubMed ID: 37171492
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of high-grade glioma and primary central nervous system lymphoma: Multiparametric imaging of the enhancing tumor and peritumoral regions based on hybrid
Zhang S; Wang J; Wang K; Li X; Zhao X; Chen Q; Zhang W; Ai L
Eur J Radiol; 2022 May; 150():110235. PubMed ID: 35290912
[TBL] [Abstract][Full Text] [Related]
14. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
[TBL] [Abstract][Full Text] [Related]
15. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ
J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.
Kawai N; Miyake K; Yamamoto Y; Nishiyama Y; Tamiya T
Biomed Res Int; 2013; 2013():247152. PubMed ID: 23844359
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging.
Xi YB; Kang XW; Wang N; Liu TT; Zhu YQ; Cheng G; Wang K; Li C; Guo F; Yin H
Eur J Radiol; 2019 Mar; 112():59-64. PubMed ID: 30777220
[TBL] [Abstract][Full Text] [Related]
19. Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation.
Yamaguchi S; Hirata K; Kaneko S; Kobayashi H; Shiga T; Kobayashi K; Onimaru R; Shirato H; Tamaki N; Terasaka S; Houkin K
Acta Neurochir (Wien); 2015 Feb; 157(2):187-94. PubMed ID: 25488176
[TBL] [Abstract][Full Text] [Related]
20. Distinguishing between primary central nervous system lymphoma and glioblastoma using [18F]fluoromisonidazole and [18F]FDG PET.
Uchinomura S; Mitamura K; Norikane T; Yamamoto Y; Oishi A; Hatakeyama T; Miyake K; Nishiyama Y
Nucl Med Commun; 2022 Mar; 43(3):270-274. PubMed ID: 34864812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
